Finance

Lists
SNW:ETR
Sanofi SA
€ 71.78
-0.60%
(-0.43) 1D
9-р сарын 25, 17:35:43 (GMT+2)  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SNW...
Open
€ 71.94
High
€ 72.06
Low
€ 71.00
Mkt. cap
86.50 тэрбум
Avg. vol.
9.06 мян
Volume
19.52 мян
P/E ratio
22.02
52-wk high
€ 90.75
52-wk low
€ 71.00
EPS
€ 3.26
Shares outstanding
1.25 тэрбум
No. of employees
75 мян
Open
€ 71.94
High
€ 72.06
Low
€ 71.00
Mkt. cap
86.50 тэрбум
Avg. vol.
9.06 мян
Volume
19.52 мян
P/E ratio
22.02
52-wk high
€ 90.75
52-wk low
€ 71.00
EPS
€ 3.26
Shares outstanding
1.25 тэрбум
No. of employees
75 мян
News stories
From web sources and news partners
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOBelén Garijo | Paul Hudson
Employees74.8 мян
Founded1973
HeadquartersПарис, Иль-де-Франс, Франц
SectorPharmaceutical industry
Websitesanofi.com
Last report
2026 оны 7-р сарын 30
Fiscal period
Q2 2026
EPS / Est. (EUR)
- / € 1.90
Revenue / Est. (EUR)
12.30 тэрбум / 10.89 тэрбум
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
13.17 тэрбум
12.20 тэрбум
11.24 тэрбум
12.30 тэрбум
Cost of goods sold
3.41 тэрбум
3.63 тэрбум
3.06 тэрбум
2.89 тэрбум
Cost of revenue
3.41 тэрбум
3.63 тэрбум
3.06 тэрбум
2.89 тэрбум
Research and development expenses
1.83 тэрбум
2.29 тэрбум
1.75 тэрбум
2.23 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.29 тэрбум
2.82 тэрбум
2.33 тэрбум
2.49 тэрбум
Operating expense
5.97 тэрбум
6.84 тэрбум
5.94 тэрбум
6.82 тэрбум
Total operating expenses
9.39 тэрбум
10.46 тэрбум
9.00 тэрбум
9.71 тэрбум
Operating income
3.78 тэрбум
1.74 тэрбум
2.25 тэрбум
2.59 тэрбум
Other non operating income
-
122.00 сая
-40.00 сая
-91.00 сая
EBT including unusual items
3.51 тэрбум
-1.16 тэрбум
2.01 тэрбум
828.00 сая
EBT excluding unusual items
3.67 тэрбум
1.70 тэрбум
2.14 тэрбум
2.40 тэрбум
Income tax expense
680.00 сая
-348.00 сая
420.00 сая
451.00 сая
Effective tax rate
19.38%
30.13%
20.85%
54.47%
Other operating expenses
1.39 тэрбум
1.19 тэрбум
1.33 тэрбум
1.55 тэрбум
Net income
2.80 тэрбум
-801.00 сая
1.61 тэрбум
343.00 сая
Net profit margin
21.28%
-6.56%
14.35%
2.79%
Earnings per share
-
1.53
1.88
-
Interest and investment income
114.00 сая
79.00 сая
60.00 сая
64.00 сая
Interest expense
-227.00 сая
-
-138.00 сая
-153.00 сая
Net interest expenses
-113.00 сая
79.00 сая
-78.00 сая
-89.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
4.20 тэрбум
3.49 тэрбум
2.78 тэрбум
3.83 тэрбум
Gain or loss from assets sale
266.00 сая
-79.00 сая
-
-9.00 сая
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс